Halozyme Announces Appointment of Jim Daly to its Board of Directors

SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of James "Jim" Daly to its Board of Directors. Mr. Daly is a highly respected biopharmaceutical executive with more than three decades of commercial leadership experience and a proven track record of shaping the profile of innovative therapies resulting in highly successful launches of respiratory, oncology and immunology therapies.

"We are delighted to welcome Jim back to Halozyme's Board of Directors," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "Jim brings exceptional industry knowledge, commercial expertise, strategic insight, and governance experience. His extensive background leading the launches and growth of multiple blockbuster therapies will be invaluable as Halozyme continues to expand the number of products using our subcutaneous (SC) delivery technologies, ENHANZE, and our two hyperconcentration technologies, Hypercon and Aerocon."

Mr. Daly previously served on Halozyme's Board of Directors and has held senior commercial leadership roles across leading global biopharmaceutical companies.

He served as Executive Vice President and Chief Commercial Officer of Incyte Corporation from 2012 to 2015. Prior to Incyte, he spent a decade at Amgen, where he held senior commercial leadership positions, including his most recent role as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Earlier in his career, Mr. Daly spent more than 16 years at Glaxo Wellcome/GlaxoSmithKline, where he held positions of increasing responsibility, including Senior Vice President and General Manager of the U.S. respiratory business.

"I am pleased to rejoin Halozyme's Board at such an exciting time in the company's evolution," said Mr. Daly. "Halozyme has created an impressive portfolio of SC delivery technologies, with ENHANZE the clear gold standard in terms of large volume SC delivery, and Hypercon and Aerocon leading the way to enabling more at home delivery of biologic medicines. I am excited to work with the management team and the Board to continue to transform the patient treatment experience and potentially outcomes."

Mr. Daly currently serves on the boards of Acadia Pharmaceuticals, Madrigal Pharmaceuticals and Cytokinetics. He previously served on the boards of argenx, Bellicum Pharmaceuticals and Chimerix.

He holds a Bachelor of Science in Pharmacy and an M.B.A. from the University at Buffalo, State University of New York.

About Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE^® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE^® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V., GSK, and Incyte.

Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration technology, recently renamed as Aerocon™. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at‑home and healthcare‑provider settings. Aerocon's polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Aerocon™ complement ENHANZE^® by enabling creation and delivery of highly concentrated biologics. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly, argenx, Vertex Pharmaceuticals and Oruka Therapeutics.

Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex^® and XYOSTED^®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.

For more information, visit www.halozyme.com and connect with us on LinkedIn.

Safe Harbor Statement

This press release may include forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential and statements regarding future performance and growth of Halozyme's business. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans", "will be" and similar expressions. Although Halozyme believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Halozyme, that could cause actual results and developments to differ materially from those expressed in the forward-looking information and statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors. These and other factors that may result in differences are discussed in greater detail in the Company's most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Halozyme undertakes no obligation to update or revise any forward-looking statements or any other information contained herein.

Contact:

Tram Bui

VP, Investor Relations and Corporate Communications

609-333-7668

tbui@halozyme.com 

SOURCE Halozyme Therapeutics, Inc.